Polyprotein Malaria Vaccine FP9 PP and MVA (EMVI call 2002)

A Plasmodium falciparum Candidate Vaccine Based on a Six Antigen Polyprotein Encoded by Recombinant Poxviruses

Inventor:                                       Prof. Adrian Hill, University of Oxford
Clinical Trial Principal Investigator:  Prof. Adrian Hill

Product Development
Product development took place as a result of a successful proposal submitted by the University of Oxford to the EMVI call 1998.

Clinical Development
Sponsored by EMVI
A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates Fp9 PP and MVA PP in Healthy Adults Using a Prime Boost Delivery Schedule

Sponsored by EMVI
A Phase IIa non-randomised controlled challenge trial:
Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with the polyprotein malaria vaccines “FP9-PP,and MVA-PP” and control non-vaccinated volunteers

A paper is being drafted.